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The PI3-kinase (PI3K) pathway regulates many cellular processes,
especially cell metabolism, cell survival, and apoptosis. Phospha-
tidylinositol-3,4,5-trisphosphate (PIP3), the product of PI3K activity
and a key signalingmolecule, acts by recruiting pleckstrin-homology
(PH) domain-containing proteins to cell membranes. Here, we de-
scribe a new structural class of nonphosphoinositide small molecule
antagonists (PITenins, PITs) of PIP3–PH domain interactions (IC50
ranges from 13.4 to 31 μM in PIP3/Akt PH domain binding assay).
PITs inhibit interactions of a number of PIP3-binding PH domains,
including those of Akt and PDK1, without affecting several PIP2-
selective PH domains. As a result, PITs suppress the PI3K-PDK1-Akt
pathway and trigger metabolic stress and apoptosis. A PIT-1 analog
displayed significant antitumor activity in vivo, including inhibition
of tumor growth and induction of apoptosis. Overall, our studies
demonstrate the feasibility of developing specific small molecule
antagonists of PIP3 signaling.
PIP3 antagonist | anticancer
Dysregulation of the phosphoinositide 3-kinase (PI3K) path-way has been implicated in many human diseases. Hyper-
activation of this pathway is known to play an important role in
tumorigenesis, whereas deficiencies contribute to the development
of type II diabetes. Therefore, this pathway offers promising tar-
gets for the development of drugs to combat these diseases (1, 2).
Class I PI3Ks (α, β, and γ) are recruited to the plasma mem-
brane in response to growth factor and hormone stimulation
to mediate the phosphorylation of lipid phosphatidylinositol-
4,5-bisphosphate (PIP2), generating phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which orchestrates multiple downstream
intracellular signaling events (2). PIP3 signaling is terminated by
the phosphatase PTEN, which dephosphorylates PIP3. Genetic
alterations targeting PTEN are among the most frequent muta-
tions in human cancers, indicating a critical role of uncontrolled
signaling through PIP3 in tumorigenesis and metastasis (3). This
conclusion is reinforced by transgenic studies establishing that
loss of PTEN leads to tumorigenesis (1).
PIP3 controls a complex cellular signaling network regulating
cell growth, proliferation, and survival. PIP3 target proteins are
located in the cytosol of unstimulated cells and are recruited to the
membrane through pleckstrin-homology (PH) domain-mediated
binding to newly formed PIP3. Membrane translocation and acti-
vation of the PIP3 target proteins initiate a variety of local re-
sponses, including assembly of signaling complexes and priming
of protein kinase cascades (1, 2). PIP3 regulates an array of PH
domain-containing proteins (4), such as serine-threonine kinases
Akt and PDK1, GRP1, a GDP/GTP exchange factor of ADP
ribosylating factor 6, and protein tyrosine kinases of the Bruton’s
tyrosine kinase (Btk) and Tec families (5, 6). This diversity in PIP3
signaling makes it one of the most important second messengers
downstream from growth factor and oncogene signals. A particu-
larly important example of PIP3-dependent activation is that of
serine-threonine kinase Akt. It is achieved both through the
binding of Akt PH domain to PIP3 andmembrane translocation of
another target of PIP3, PDK1, which phosphorylates and activates
Akt. The Akt family plays a fundamental role in cell survival,
growth, and energy metabolism (1, 7).
Although lipid–protein interactions mediate PI3K signaling and
are frequently deregulated in cancer, most therapeutic strategies
targeting the PI3K pathway have focused on inhibitors for down-
stream targets, including PDK1 (8) and Akt (9). Phospholipid–
protein interactions have not been as actively targeted, even
though lipid molecules are among the most important classes of
second messengers. It is surprising considering that they represent
“prototypic” small molecule–protein interactions usually involving
well-defined binding sites (10). Conceptually, protein–lipid inter-
actions may be more readily targetable compared with protein–
protein interactions, which frequently involve interactions of ex-
tended flat protein surfaces difficult to disrupt by small molecules.
Here, we have pursued the identification of the small molecule
antagonists of PIP3/protein binding. We report the discovery of
selective nonphosphoinositide PIP3 inhibitors, termed PITenins
(PITs). PIT-1, selected in a screen of ≈50,000 small molecules by
using a PIP3/Akt PH domain binding assay, has been extensively
characterized. Our studies demonstrate that PIT-1 effectively
inhibits cancer cell survival and induces cell apoptosis by specifi-
cally inhibiting PIP3-dependent PI3K-PDK1-Akt signaling, re-
sulting in significant antitumor activity in vivo. Thus, we show
not only a methodology usable to identify additional classes of
phospholipid–protein interactions, but also the feasibility of de-
veloping cell-permeable specific small molecule nonlipid antago-
nists of lipid–protein interactions.
Results
Identification of PIT-1 as a Specific PIP3 Antagonist. To identify
compounds that disrupt the interaction between PIP3 and PH
domains, we developed a high-throughput fluorescence polari-
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zation (FP)-binding assay by using recombinant 1–123 amino acid
N-terminal fragment of human Akt1, encompassing the PH do-
main (PH123 protein), and a fluorescent NBD-labeled PIP3
molecule. The R86A mutation in the PH domain, shown to disrupt
PIP3–PH interaction (11), completely abrogated fluorescent PIP3
binding by PH123 (Fig. S1A), validating the assay. Our screen of
≈50,000 diverse small molecules using this FP assay identified two
distinct inhibitors of PIP3/PH domain binding, which were termed
PIT-1 and PIT-2 (Fig. 1A). These molecules disrupted PIP3/Akt
PH domain binding with IC50 = 31.03 and 31.52 μM for PIT-1 and
PIT-2, respectively (Fig. 1B). Although giving similar results to
PIT-1, PIT-2 displayed limited stability and was used primarily to
confirm the major conclusions. Analysis of commercial PIT-1
analogs suggested that thiourea and hydroxyl groups are critical for
the activity in vitro and revealed closely related inactive analogs of
PIT-1, termed PIT-1i-1 and PIT-1i-2 (Fig. 1A), which have been
used as negative controls. Besides the Akt PH domain, PIT-1 and
PIT-2 also inhibited the binding of PIP3 to the PH domains of
PDK1, GRP1, and ARNO with lower affinity (Fig. 1B and Fig. S1
B, C, and F) and failed to inhibit PIP3 binding to the PIP3-specific
PH domain of Btk (Fig. 1B and Fig. S1G). Thus, PITs exhibited
selectivity toward a distinct subset of PIP3-specific PH domains.
Furthermore, PITs failed to inhibit PIP2-specific interactions be-
tween PI-4,5-P2 and PH domain of PLC-δ (4), and between PI-3,4-
P2 and TAPP1 or TAPP2 (12) (Fig. 1B and Fig. S1 D and E). A
lipid overlay assay, which detects binding of recombinant proteins
to membrane-spotted lipids, confirmed both the inhibitory effect
of PIT-1 on PIP3/Akt PH domain binding and the failure to inhibit
the binding of PIP2 to PLC-δ PH domain seen in FP assay (Fig.
S1I). PITs exhibit a weaker, but detectable, inhibition on the
binding of PI-3,4-P2 to Akt PH domain (Fig. S1H), consistent with
the notion that PITs targeting Akt PH domain binding pocket,
rather than a lipid. These data suggest that PIT-1 and PIT-2 rep-
resent unique nonphosphoinositide-related selective antagonists of
PIP3/PH domain binding.
To characterize the mode of action of PIT-1, we performed
NMR-basedanalysis of PIT-1binding to thePHdomain ofAkt.We
found PIT-1 induces significant changes in the 2D HSQC 1H-15N
correlation spectrum of Akt PH123, indicative of the direct PIT-1/
Akt PH domain binding (Fig. S2A). We titrated Akt PH123 with
PIT-1 to identify the residues affected by binding. Using published
Akt2 HSQC peak assignments (13), we observed that the residues
W22, Y26, and N54, located in the PIP3 binding pocket of the Akt
PH domain, are affected by PIT-1. We found that PIT-1 had no
effect on the R86A PH domain mutant, which lacks PIP3 binding
activity, confirming the PIP3-mimetic nature of PIT-1. Using this
information, wepropose a bindingmodel of PIT-1 on the surface of
the Akt PH domain in which the PIT-1 binding site overlaps with
the PIP3 binding site. Consistent with NMR data, W22 and Y26
flank the RPR motif that interacts with the 3-phosphate of PIP3
and the nitro group of PIT-1, whereas N54 packs against the ter-
minal phenyl group of PIT-1 and does not interact with PIP3 (Fig.
S2 B and C). We confirmed the direct binding of PIT-1 to Akt PH
domain by using SPR, which showed that the molecule is a re-
versible binder with Kd of ≈43.2 μM (Fig. S1J).
PIT-1 Inhibits the PIP3-Mediated PI3K-PDK1-Akt Signaling Pathway.
To begin characterizing cellular activities of PITs, we performed
a PH domain translocation assay that measures PIP3-mediated
association of the GFP-fused PH domains with the plasma
membrane (5). As shown in Fig. 2A, both PIT-1 and PIT-2 signi-
ficantly inhibited the translocation of PIP3-specific Akt andGRP1
PH domains in response to PDGF stimulation. Neither PIT-1i-1
nor PIT-1i-2 inhibited the translocation of Akt and GRP1 PH
domains (Fig. 2A and Fig. S3B). No inhibition of translocation was
observed with either the Btk PH domain, which does not bind
PITs, or PIP2-specific PLC-δ, TAPP1, and TAPP2 PH domains
(Fig. 2A and Fig. S3 A and B). These results, like the FP analysis,
indicate that PITs are specific PIP3 antagonists with selectivity
toward a distinct subset of PIP3-specific PH domains.
Next, we examined the effect of PITs on PIP3-mediated PI3K-
PDK1-Akt signaling. We first analyzed U87MG glioblastoma cells,
which showelevatedbasal levels ofPIP3becauseof the loss ofPTEN
(14). Human gliomas frequently display increased PIP3 synthesis
due to PI3K and PTENmutations, and inhibition of PI3K signaling
has emerged as a promising new therapeutic strategy against this
cancer (15). Both PIT-1 and PIT-2 suppressed PI3K-PDK1-Akt-
dependent phosphorylation events in U87MG cells. Inactive ana-
logs PIT-1i-1 and PIT-1i-2 failed to inhibit PDK1/Akt signaling
(Fig. 2B and Fig. S3C). Similarly, PIT-1 significantly suppressed
PI3K-PDK1-Akt signaling in growth factor-stimulated breast car-
cinomaSUM159cells (Fig. S3D).Thesedata confirm thatPIT-1and
PIT-2 inhibit PI3K-PDK1-Akt signaling. Moreover, PITs equally
inhibited phosphorylation of Akt1, Akt2, and Akt3 (Fig. S3E),
consistent with >70% identity between their PH domains. We also
demonstrated that PITs treatment failed to induce changes of PIP3
levels in cells, suggesting the inhibition of Akt phosphorylation in
cell-based assays was not from inhibition of PI3-K itself (Fig. S3G).
Comparison of PIT-1 with several previously reported Akt
inhibitors showed differences in mechanism. Neither Akt inhi-
bitor X nor allosteric inhibitor VIII blocked membrane trans-
location of Akt PH domain (Fig. S4A andB). Furthermore, PIT-1
and the Akt kinase inhibitors acted additively in attenuating Akt
activation, phosphorylation of downstream targets, and inhibition
of cell survival. Conversely, no additive effect was observed when
Akt inhibitor VIII and X were combined (Fig. S4C andD). These
data emphasize that PITs represent a distinct class of Akt inhib-
itors and suggest mechanistic differences could be exploited to
Fig. 1. The identification of PIT-1 as a specific PIP3 inhibitor. (A) Structures of
the PITs and inactive analogs. (B) Specificity analysis of phosphoinositide-PH
domain inhibition by PITs. TMR-conjugated PI-3,4,5-P3 (15 nM)were incubated
with 5 μM Akt PH domain, 100 nM PDK1 or Btk PH domain. TMR-conjugated
PI-4,5-P2 (15nM)were incubatedwith100nMPLC-δ PHdomain in thepresence
or absence of PITs (6.25–200 μM) for 30 min, followed by FP measurement.
Miao et al. PNAS | November 16, 2010 | vol. 107 | no. 46 | 20127
PH
A
RM
A
CO
LO
G
Y
achieve efficient inhibition of Akt signaling by combining PH
domain-targeting PITs with inhibitors of the Akt kinase activity.
PIT-1 Preferentially Reduces Viability of PTEN-Deficient Glioblastoma
Cells. Given the critical role of PIP3-dependent Akt signaling in
promoting cell survival, we tested the effect of PITs on cancer cell
viability. Both PIT-1 and PIT-2 reduced viability of multiple cancer
cell lines in a dose- and time-dependent manner (Fig. 3A and Fig.
S5 A and B). PIT-1 consistently suppressed long-term colony for-
mationbyU87MGcells (Fig. S5C).Exposureof cells toPITs resulted
ineventual cell rounding, lossof adhesion, andcell death (Fig. 3B). In
contrast, inactive analogs PIT-1i-1 and PIT-1i-2 caused no loss of
viability (Fig. 3B and Fig. S5 A and B). Previous reports (16) sug-
gested that constitutive exposure of transformed cells to oncogenic
signaling may render cancer cells hypersensitive to disruption of
oncogenic signals (“oncogene addiction”). Therefore, we next ex-
amined whether PIT-1 may cause preferential cell death in the cells
containing elevated PIP3 levels. We found the toxicity of PIT-1 was
more pronounced inU87MGcells expressing inactive PTEN than in
cells expressing wild-type PTEN (Fig. 3C). This result is consistent
with changes in Akt phosphorylation observed in PTEN-expressing
and -deficient cells. Akt phosphorylation was significantly higher in
PTEN-deficient cells, and PIT-1 inhibited it to amuch greater extent
in these cells compared withWT PTEN cells (Fig. S5H). These data
are consistent with the notion that PTEN-deficient cancer cells be-
come overly dependent on PIP3 signaling and, therefore, are hy-
persensitive to the disruption of this pathway compared with that of
wild-type PTEN-expressing cells. In addition to U87MG cells, we
have also examined MCF7 cells, which express E545K PI3KCA
mutant, and confirmed that PITs are able to inhibit Akt activation in
the presence of a constitutively active PI3K (Fig. S3F).
Up-regulation of PI3K/Akt signaling is an important mecha-
nism of chemoresistance of cancer cells (17). In particular, in-
hibition of PI3K and Akt was shown to sensitize cancer cells to
killing by a TNFα family member, TRAIL. TRAIL represents a
particularly promising anticancer agent because of its intrinsic se-
lectivity toward cancer cells (18). At the same time, overactivation
of intracellular antiapoptotic mechanisms has been shown to at-
tenuate cancer cell sensitivity to TRAIL (19). Although U87MG
cells are indeed resistant to TRAIL, we found that PIT-1 sub-
stantially sensitizedU87MG cells to killing by TRAIL (Fig. 3E and
Fig. S5D). Similar results were obtained by using PIT-2 as well as
Akt kinase inhibitor and PI3K inhibitor, LY294002, but not PIT-
1i-1 (Fig. 3E and Fig. S5D–G). Furthermore, this effect was again
significantly more pronounced in U87MG cells expressing inactive
PTEN than in cells expressing wild-type PTEN (Fig. S5J).
To confirm the mode of action of PIT-1 in the cells is directly
related to the inhibition of PIP3/Akt PH domain interaction, we
tested induction of cell death in the cells overexpressing constitu-
tively active Akt lacking PH domain, but containing a membrane-
targeting myristoylation signal. We found that overexpression of
PH domain-deficient Akt indeed significantly protected U87MG
cells from PIT-1 killing (P < 0.05, IC50 changed from 37.4 to 103.6
μM; Fig. S5K). A similar result was also obtained with PIT-2 (IC50
changed from 38.7 to 112.5 μM; Fig. S5L).
Fig. 2. PIT-1 inhibits PI3K/PDK1/Akt signaling in cancer cells. (A) PITs inhibit
growth factor-induced plasma membrane translocation of the PIP3-specific
Akt and GRP1, but not that of the Btk PH domain. SUM159 cells were
transfected with the GFP-fusion vectors, serum starved overnight, and in-
cubated with 100 μM PITs or PIT-1is for 1 h, followed by stimulation with 100
ng/mL PDGF for 5 min. The representative fluorescent images are shown. (B)
PIT-1 inhibits Akt signaling pathway in U87MG cells. U87MG cells were
treated with PIT-1 or PIT-1i-1 (25, 50, 100 μM) for 12 h, and the indicated
PIP3-dependent phosphorylation events were evaluated by Western blot.
Fig. 3. PIT-1 reduces cell viability, displays preferential effect in PTEN-
deficient cells, andsynergizeswithTRAIL. (A) PIT-1 reduces theviabilityofmultiple
cancer cells.Differentcancer cell lineswere incubatedwithPIT-1 (12.5–100μM)for
48h.Cell viabilitywasdeterminedbyusingATPassay. (B) PITs, butnot the inactive
derivatives, reduce viability of U87MG cells. U87MG cells were incubated with
compounds for48h,andtherepresentativebrightfield imagesof cells are shown.
(C) The toxicity of PIT-1 is more pronounced in PTEN-deficient U87MG cells
expressing R130M inactive mutant of PTEN compared with the cells expressing
wild-typePTEN.After treatmentwithPIT-1 (25,50,100μM)for48h,celldeathwas
analyzed by using Sytox cell death assay. (D) Loss of cell viability caused by PITs, as
well asAkt inhibitor, ismore pronounced in Akt1-expressing cells comparedwith
the triple knockout cells deficient in all Akt isoforms. Cells were incubated with
100 μM PIT-1, PIT-2, PIT-1i-1, or 10 μM Akt inhibitor VIII for 24 h, followed by
analysis of cell viability by using ATP assay. (E) PITs, as well as Akt inhibitor, sen-
sitize U87MG cells to killing by TRAIL. U87MG cells were incubated with 100 μM
PIT-1,PIT-2, PIT-1i-1, or10μMAkt inhibitorVIII in thepresenceorabsenceof10ng/
mL TRAIL for 24 h, followed by cell viability analysis by using ATP assay.
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However, inhibition of cell death by Myr-Akt was not complete.
This result could be explained by inhibition of another PIT-1 target,
PDK1 (Fig. 1B and Table S1), which regulates cell survival both
through Akt as well as independently (20). Akt Thr308 phosphor-
ylation is mediated by PDK1, so PIP3-dependent membrane co-
localization of bothAkt andPDK1 contribute toAkt activation and
cell survival. We indeed observed that PIT-1 and PIT-2 inhibited
phosphorylation of Myr-Akt (Fig. S5N), further suggesting that
PDK1 is also targeted by PITs in the cells. In concert with the
possible role of PDK1 in PIT-induced toxicity, a significantly more
pronounced inhibition of cell death by Myr-Akt was observed in
cells treated with PIT-6 (IC50 changed from 10.6 to 168.8 μM; Fig.
S5M and Table S1). This analog of PIT-1 is selective for Akt PH
domain versus PDK1 PH domain (Table S1). Finally, the highest
cellular activity displayed by PIT-7, which targets Akt more effi-
ciently and retains PDK1 binding (Table S1), also supports the
notion that both PDK1 and Akt mediate PITs’ toxicity.
Finally, the loss of viability caused by both PIT-1 and PIT-2 was
more pronounced (P < 0.01) in Akt1-expressing cells compared
with triple knockout fibroblasts deficient in all Akt isoforms (21)
(Fig. 3D and Fig. S5I). Importantly, Akt kinase inhibitor displayed
a similar effect (Fig. 3D and Fig. S5I). Overall, these data confirm
the contribution of Akt to the PIT-1-induced cell death.
PIT-1 Induces Apoptosis and Metabolic Stress. Because PI3K/PIP3/
Akt signaling plays a critical role in the inhibition of apoptosis (7),
we examined whether PITs induce apoptosis. Cell death triggered
by PIT-1 and PIT-2 alone or in combination with TRAIL was
inhibited by a pan-caspase inhibitor zVAD.fmk (Fig. 4A and Fig.
S6A). We also found that killing of cells by PIT-1 and PIT-2 was
reduced in cells lacking two important apoptosis mediators, Bax
and Bak (Fig. S6B). Cell death induced by PIT-1 showed multiple
apoptotic features. Namely, PIT-1 and PIT-2 treatment caused
a significant increase in subG1DNAcontent in cells (P< 0.01) (Fig.
4B). In addition, the nuclei of treated cells had a condensed and
fragmented morphology, characteristic for apoptosis (Fig. S6C).
Finally, Western blot analysis showed that PIT-1 induced the
cleavage/activation of a critical apoptosis executioner molecule,
caspase-3, and its substrate, PARP(Fig. 4C). Thesedata suggest the
activation of apoptosis by PITmolecules, consistent with inhibition
of antiapoptotic activity by the Akt-mediated signaling pathway.
Changes in cellular metabolism have recently emerged as an
important component of the PI3K/PIP3/Akt signaling, contribut-
ing to regulation of cell viability (7). Thus, we next investigated
whether PIT-1 causes dysregulation of energy homeostasis and
induction of metabolic stress in cancer cells. PIT-1 indeed induced
significant increases in phosphorylation of AMP-activated protein
kinase (AMPK), a key factor in regulation of energy homeostasis
activated by metabolic stress (22), as well as increased phosphor-
ylation of its main substrate acetyl-CoA carboxylase (ACC) (Fig.
4D). Furthermore, we observed increased formation of the auto-
phagic marker LC3-II (Fig. S6D), which showed characteristic
perinuclear punctuate staining (Fig. S6E). Electron microscopy
showed the appearance of characteristic double membrane-
enclosed autophagic vesicles even at the early stages of PIT-1 treat-
ment (Fig. S6F). This result indicates the induction of autophagy,
a large-scale catabolic process playing a key role in mediating
cellular adaptation to metabolic stress (23), consistent with the
induction of metabolic stress by PIT-1. It is also consistent with the
established role of Akt as an inhibitor of autophagy (24).
PIT-1 and Its Analogs, the Inhibition of in Vivo Tumor Growth. Given
the significant inhibition of PI3K/PIP3/Akt signaling and cancer
cell survival by PIT-1 in vitro, we examined its anticancer activity
in vivo. Because of limited aqueous solubility of PIT-1, we used
a dimethyl analog of PIT-1, DM-PIT-1 (Fig. 1A) for in vivo
analysis, because we found that it can be effectively incorporated
(unlike PIT-1) into the long circulating polyethylene glycol-
phosphoethanolamine (PEG-PE) mixed micelles. We have
confirmed that DM-PIT-1 did not display any significant differ-
ences from PIT-1 across the range of assays used to characterize
PIT-1 (Figs. 1B and 2A, Fig. S1 B–D, and Fig. S3 A and B). DM-
PIT-1 displayed somewhat increased activity compared with PIT-
1 in inhibiting PI3K-PDK1-Akt signaling (Fig. S7A) and inducing
cell death (Fig. S7B), which may be associated with better cell
permeability arising from its increased lipophilicity. The in-
corporation of DM-PIT-1 into PEG-PE mixed micelles (DM-
PIT-1-M) significantly increased solubility (up to 1 mM) and had
no influence on induction of cell death (Fig. 5A).
We next examined the effect of i.v. administration of both
unencapsulated DM-PIT-1 and DM-PIT-1-M on syngeneic 4T1
breast cancer growth in BALB/c mice. We found both of them
significantly attenuated tumor growth in vivo compared with the
control after 8-d administration (P< 0.01).Using themicellar form
ofDM-PIT-1 allowed a substantially higher dose (1mg/kg per day)
of the drug compared with the free drug (0.4 mg/kg per day) be-
cause of the increased solubility, leading to a more pronounced
inhibition of tumor growth (P< 0.01). In particular, on day 8 of the
treatment, free DM-PIT-1 and DM-PIT-1-M reduced tumor vol-
ume by 58.1 and 95.2%, respectively, compared with controls (Fig.
5B). Administration of both DM-PIT-1 formulations was well
tolerated by healthy mice without any signs of overt toxicity or loss
of weight (Fig. S7C). Consistent with the in vitro data, analysis of
the tumors from DM-PIT-1-treated animals showed widespread
induction of apoptosis measured by using TUNEL assay. In ad-
dition, the nuclei of treated cells displayed characteristic nuclear
fragmentation (Fig. 5C and Fig. S7D).Western blot results showed
that compound treatment caused a significant increase in the
cleavage/activation of caspase-3, as well as cleavage of PARP,
again, indicative of apoptosis. Furthermore, consistent with the in
vitro mechanism of action, administration of the compound effi-
ciently suppressed the PI3K/PIP3/Akt signaling in the tumor cells
(Fig. 5D and Fig. S7E).
Fig. 4. PIT-1 induces apoptosis and metabolic stress in cancer cells. (A) Cell
death triggered by PIT-1 alone or in combination with TRAIL is inhibited by
pan-caspase inhibitor zVAD.fmk. U87MG cells were incubated with 100 μM
zVAD.fmk together with PIT-1 (25, 50, 100 μM) in the presence or absence of
10 ng/mL TRAIL for 24 h and analyzed with Sytox cell death assay. (B) PITs
treatment causes a significant increase in subG1 DNA content in U87MG cells.
U87MG cells were incubatedwith PIT-1 or PIT-2 (25, 50, 100 μM) for 48 h,fixed,
and stained with PI for 30 min. The percentage of cells with hypodiploid DNA
was determined by FACS. (C) PIT-1 induces caspase-3 activation. U87MG cells
were treated with PIT-1 (25, 50, 100 μM) for 48 h. Cleavage of caspase-3 and
PARP was analyzed by Western blot. (D) Treatment of U87MG cells with 100
μM PIT-1 for 48 h induces an increase in phosphorylation of AMPK and its
main substrate, ACC. **P < 0.01 compared with control group.
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Modulation of Selectivity of PIT-1 Toward Akt PH Domain. PIT-1 and
DM-PIT-1 display selectivity toward a subset of PIP3-binding PH
domains. To explore whether we could achieve improved selec-
tivity toward a particular PH domain, we have compared the
crystal structures of the PH domains of Akt, PDK1, and GRP1
(Protein Data Bank ID codes: 1UNQ, 1W1D, and 1FHX). Spe-
cifically we aimed to take advantage of the nonconservative sub-
stitution in PIP3 binding pocket of Leu52 of Akt1 for structurally
equivalent Arg305 of GRP1 and Lys495 of PDK1 (Fig. S2C).
These residues were modeled to be in the proximity of the nitro
group of PIT-1, and we hypothesized that hydrophobic groups in
R2 and R3 positions of PIT-1 would be preferred for Akt and
disfavored for PDK1 andGRP1 binding. Indeed, PIT-4, -5, and -6
exhibit improved Akt potency and selectivity (Fig. S8 A, E, and F
and Table S1) compared with PIT-1. Consistently, SPR analysis
showed that PIT-6 has an increased binding to Akt PH domain
(Kd is≈20.3 μM) compared with PIT-1 (Kd is≈43.2 μM) (Fig. S1 J
and K). Importantly, consistent with the proposed mechanism of
cellular activity of PIT-1, increased affinity of PIT-1 analogs to-
wardAkt led to a substantially higher inhibition of Akt signaling in
U87MG cells (Fig. S8B) as well as increased cytotoxicity (Fig. S8C
and Table S1). Further, targeting of PDK1may provide additional
benefit, as PIT-7, displaying increased Akt binding and some
PDK1 binding, exhibited the strongest activity in suppressing Akt
signaling, and reducing cancer cell viability (Fig. S8 A–C, E, G,
and H and Table S1). Toxicity of new PIT-1 analogs was signifi-
cantly (P < 0.05) attenuated by overexpression of PH domain-
deficient activated Akt, consistent with the contribution of PITs/
Akt PH domain interaction to cell death (Fig. S8D). The new
PIT-1 analogs also remained inactive toward PIP3/Btk PH and
PIP2/PLC-δ/TAPP1/TAPP2 PH domain. Overall, these data
suggest that a rational approach can be used for selectively tar-
geting PH domains. Specifically, activity of PIT-1 toward Akt and
induction of cell death can be significantly increased by targeted
chemotype modifications coupled with elimination of features
that can present metabolic liabilities.
Discussion
Here, we describe PITs, a new class of specific nonphosphoin-
ositide small molecule PIP3 antagonists (IC50 ranges from 13.4 to
31 μM in PIP3/Akt PH domain binding assay and from 6.6 to 39.9
μM in cell viability assay). These molecules showed activity against
PIP3-dependent PI3K/PDK1/Akt signaling in vitro and significant
antitumor activity in vivo. PITs can trigger an array of cellular
responses including inhibition of cell survival, induction of apo-
ptosis, restoration of cellular sensitivity to TRAIL, and activation
of metabolic stress. Importantly, these effects are preferentially
induced in PTEN-deficient U87MG cells, suggesting inhibition of
PIP3 and Akt signaling as a promising strategy against human
tumors characterized by elevated PIP3 levels such as glioblastomas
(15). In vitro activities of PIT-1 translated into pronounced inhi-
bition of tumor growth in vivo by PIT-1 analog, DM-PIT-1. At the
same time, DM-PIT-1 is well tolerated upon systemic adminis-
tration in mice. Overall, our studies establish the feasibility of
developing anticancer agents, targeting the PI3K pathway through
specific, selective disruption of PIP3/PH domain interactions.
Multiple lines of evidence argue that the effects of PITs are
specific for PH domains and the PI3K/PDK1/Akt pathway. First,
two structurally distinctmolecules, PIT-1 andPIT-2, isolated based
on the inhibition of the PIP3 interaction with the Akt PH domain
in vitro, displayed very similar cellular activities in a wide range of
assays. Conversely, the structurally related PIT-1i-1 and PIT-1i-2
molecules lacked activity in both in vitro PH domain binding and
all cell-based assays. These results provide an important validation
of the mode of action of PITs. Second, cellular activities of PITs
paralleled that of the previously identified Akt kinase activity in-
hibitors in a number of assays, consistent with the role of Akt as an
important mediator of the PIP3 signaling. Third, multiple activities
of PITs can be significantly attenuated by overexpression of the PH
domain-deficient activated Akt. Fourth, selectively increasing af-
finity of PIT-1 toward the PH domain of Akt in vitro lead to the
parallel increase inhibition of PI3K/Akt signaling and induction of
cell death, consistent with the central role of Akt in the regulation
of cell viability (Table S1). Overall, these data suggest that PIT-1
scaffold may be a promising starting point for further optimization
of the selectivity of the inhibitors toward particular PIP3-specific
PH domains and, hence, PIP3-dependent cellular functions. Al-
though initial profiling data suggest some selectivity of PIT-1 and
PIT-2 toward a subset of PIP3-binding PHdomains, this conclusion
needs to be further verified by profiling additional PH domains.
Inhibition of the PIP3/protein binding represents a powerful
approach to alter PI3K signaling, because PIP3/PH domain bind-
ing is a universal upstream step in PI3K signaling. Examples of
PIP3 antagonists, using lipid scaffolds, primarily alkylphospholi-
pids and phosphatidylinositol ether lipid analogs (PIAs), have been
described (25, 26). These molecules interact with the Akt PH do-
main and block Akt membrane translocation and activation.
However, achieving selectivity toward specific phosphoinositide
targets is likely tobedifficultwith such scaffolds.PIAmolecules, for
example, use a modified nonphosphorylated inositol headgroup.
Thus, cellular activities of PIAs may well require phosphorylation
by endogenous lipid kinases. It may be very challenging to achieve
selectivity of PIAs for a specific phosphoinositide, i.e., PIP3, versus
other phosphoinositides or in the subfamily of PIP3-binding PH
domains. At present, the selectivity profile of these molecules has
not been established andAkt PHdomain remains their only known
PIP3-dependent target. Nonphospholipid/nonphosphoinositide
smallmolecule antagonists present a goodalternative startingpoint
for the selectivemodulation of the PI3K signaling network. Several
Akt PH domain small inhibitors have been reported (27–29). One
of these molecules, triciribine phosphate (TCN-P) binds to the PH
domain of Akt with high affinity (Kd = 690 nM) and blocks its re-
Fig. 5. DM-PIT-1 inhibits in vivo tumor growth. (A) DM-PIT-1 encapsulation
into PEG-PE micelles facilitates cytotoxicity of DM-PIT-1. U87MG cells were in-
cubatedwithDM-PIT-1orDM-PIT-1-Mwithorwithout 10ng/mLTRAIL for24h,
followedbycell viabilityanalysis usingATPassay. (B) AdministrationofDM-PIT-
1 orDM-PIT-1-M for 8 d attenuates syngeneic 4T1 beast tumor growth in BALB/
c mice. After inoculation of tumor cells, DM-PIT-1 or DM-PIT-1-M was admin-
istered i.v. daily at doses of 0.4 and 1 mg/kg, respectively, for 8 d. The tumor
volumes weremeasured every two days and are shown. (C) DM-PIT-1 and DM-
PIT-1-M administration induces apoptosis of cancer cells in vivomeasuredwith
TUNELassay (green), andnucleiwere stainedwithHoechst (blue). (D) DM-PIT-1
and DM-PIT-1-M administration suppresses PI3K/PIP3/Akt signaling, and
increases cleavage of caspase-3 in tumor cells evaluated by usingWestern blot.
20130 | www.pnas.org/cgi/doi/10.1073/pnas.1004522107 Miao et al.
cruitment to plasma membrane, resulting in the induction of apo-
ptosis and inhibition of tumor growth in vivo (9, 29). TCN-P has
been recently evaluated clinically in a tailored-personalized phase I
trial where only patients whose tumors have high phosphorylated
Akt levels were accrued, which showed inhibition of tumor Akt
phosphorylation at the tolerated doses (30). PITs are a new struc-
tural class of directly competitive and selective nonphosphoin-
ositide small molecule antagonists of PIP3 active in cells, in vitro
and in vivo. Furthermore, our results suggest that this approach can
be extended beyond inhibition of just Akt PH domains, targeting
other important effectors of PIP3 signaling, such as PDK1, GRP1,
and ARNO. At the same time, taking advantage of the differences
in PH domain PIP3 binding pockets, selective inhibition of par-
ticular PH domains could be achieved through modification of
common PIT scaffolds.
Both direct ATP-competitive inhibitors of Akt and allosteric
inhibitors, targeting the interface between the PH domain and the
Akt kinase domain, have been developed (25). This work describes
a different approach to inhibition of cellular Akt signaling, tar-
geting membrane localization, and activation of the kinase. Be-
cause of a different mode of action, these inhibitors can be
combined with the existing Akt kinase inhibitors to achieve greater
efficacy in blocking Akt signaling as shown in Fig. S4. Our results
suggest a possibility of Akt-directed combination therapy. More-
over, the different mode of action of PITs may offer benefits in
blocking PIP3 signaling when combined with the existing PI3K
inhibitors. Importantly, efficient suppression of the PIP3 signaling
by PI3K inhibitors is negatively influenced by the loss of the PIP3
phosphatase PTEN, hydrolyzing preexisting pool of PIP3. PTEN is
frequently inactivated in tumors, e.g., many glioblastomas, breast,
endometrium, and colon cancers (31). Thus, combining PI3K in-
hibitors with PITs, acting downstream from the PTEN-dependent
step, may represent a promising strategy, especially against PTEN-
deficient tumors. Furthermore, cells deficient in PTEN, which are
adapted to growth in the presence of high PIP3 levels, display in-
creased sensitivity to killing by PITs, compared with the matched
cells expressing functional PTEN.
One important future direction of anticancer drug discovery is
the targeting of specific branches of the PI3K pathway, which
would limit side effects of global PI3K pathway inhibition. To this
end, we show that chemical modification of PIT-1 results in pro-
found changes in the selectivity profile of themolecule. Combining
extensive data profiling PIP3/PH domain binding (4) with further
chemicalmodification of PIT-1 ormolecules with a similarmode of
action may represent a promising approach to developing useful
tool compounds for dissecting cellular PIP3 signaling networks.
Furthermore, PIT compounds, possessing differentmode of action
profiles, could be attractive as leads for anticancer drug discovery.
Materials and Methods
PIT-1, DM-PIT-1, inactive analogs, and PIT-2 were obtained from commercial
sources. Synthesis of PIT-1 derivatives, antibodies, DNA vectors, and all other
reagents are described in detail in SI Materials and Methods. FP assay was
performed by using TMR-labeled PIP3 or PIP2 and bacterially expressed
recombinant PH domains. For lipid overlay assay, PIP3 or PIP2 was spotted on
the nitrocellulose membrane and binding of recombinant GST-PH domains
was determined by using anti-GST antibody. Cell viability was measured by
using commercial ATP, MTS, or Sytox assays. Membrane translocation of PH
domains was evaluated by using fluorescent microscopy following trans-
fection with GFP-PH vectors. Inhibition of tumor growth was determined
following 8-d i.v. administration of DM-PIT-1 in PBS or PEG-PE mixed micelles
into BALB/c mice inoculated (s.c.) with 4T1 tumors. These and all other
methods are described in detail in SI Materials and Methods.
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